Futuras estrategias terapéuticas en el tratamiento del cáncer de mama metastásico RE+/HER2-negativo: inhibidores CDK4/6 - page 6

ENDOCRINE
RESISTANCE
Upregulation of
alternative signal
transduction
pathways
Alterations of ER itself
• “Loss” due to ESR1
silencing
• Constitutional
activation of ER due
to ESR1 mutations/
fusion events
Mechanisms of Endocrine Resistance